The preparation of this consensus document has been supported by the GEICAM Breast Cancer Research Group with the aim of developing recommendations on criteria for hormone sensitivity and resistance in HER2-negative luminal MBC and facilitating clinical decision-making. Here, ERBB2 is linked to breast cancer.